Literature DB >> 11377801

Human mitochondrial DNA diseases.

T Pulkes1, M G Hanna.   

Abstract

The mitochondrial encephalomyopathies are a genetically heterogeneous group of disorders associated with impaired oxidative phosphorylation. Patients may exhibit a wide range of clinical symptoms and experience significant morbidity and mortality. There is currently no curative treatment. At present the majority of genetically defined mitochondrial encephalomyopathies are caused by mutations in mitochondrial DNA. The underlying molecular mechanisms and the complex relationship between genotype and phenotype in these mitochondrial DNA diseases remain only partially understood. We describe the key features of mitochondrial DNA genetics and outline some of the common disease phenotypes associated with mtDNA defects. A classification of pathogenic mitochondrial DNA point mutations which may have therapeutic implications is outlined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377801     DOI: 10.1016/s0169-409x(01)00124-7

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  10 in total

1.  Nuclear and mitochondrial DNA microsatellite instability in hepatocellular carcinoma in Chinese.

Authors:  Dian-Chun Fang; Li Fang; Rong-Quan Wang; Shi-Ming Yang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  MERRF and Kearns-Sayre overlap syndrome due to the mitochondrial DNA m.3291T>C mutation.

Authors:  Valentina Emmanuele; David S Silvers; Evangelia Sotiriou; Kurenai Tanji; Salvatore DiMauro; Michio Hirano
Journal:  Muscle Nerve       Date:  2011-09       Impact factor: 3.217

3.  Knowledge and awareness of mitochondrial diseases among physicians in the tertiary hospitals in Ghana.

Authors:  Eric A Mensah; Bismark Sarfo; Alfred E Yawson; Joshua Arthur; Augustine Ocloo
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

4.  The m.3244G>A mutation in mtDNA is another cause of progressive external ophthalmoplegia.

Authors:  Evangelia Sotiriou; Jorida Coku; Kurenai Tanji; Hua-bin Huang; Michio Hirano; Salvatore DiMauro
Journal:  Neuromuscul Disord       Date:  2009-03-13       Impact factor: 4.296

Review 5.  Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects.

Authors:  Gerard G M D'Souza; Sarathi V Boddapati; Volkmar Weissig
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.580

6.  A T-stem slip in human mitochondrial tRNALeu(CUN) governs its charging capacity.

Authors:  Rui Hao; Ming-Wei Zhao; Zhan-Xi Hao; Yong-Neng Yao; En-Duo Wang
Journal:  Nucleic Acids Res       Date:  2005-06-22       Impact factor: 16.971

Review 7.  Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury.

Authors:  Aida Ortega-Alonso; Camilla Stephens; M Isabel Lucena; Raúl J Andrade
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

8.  Overproduction of reactive oxygen species - obligatory or not for induction of apoptosis by anticancer drugs.

Authors:  Donika Ivanova; Zhivko Zhelev; Ichio Aoki; Rumiana Bakalova; Tatsuya Higashi
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

9.  Biological response of zebrafish embryos after short-term exposure to thifluzamide.

Authors:  Yang Yang; Wenxian Liu; Xiyan Mu; Suzhen Qi; Bin Fu; Chengju Wang
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

10.  Evaluation of 6-Hydroxydopamine and Rotenone In Vitro Neurotoxicity on Differentiated SH-SY5Y Cells Using Applied Computational Statistics.

Authors:  Rui F Simões; Paulo J Oliveira; Teresa Cunha-Oliveira; Francisco B Pereira
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.